TALZENNA 5 Overdosage

talazoparib

(

There is no specific treatment in the event of TALZENNA overdose, and symptoms of overdose are not established. In the event of overdose, treatment with TALZENNA should be stopped, and physicians should consider gastric decontamination, follow general supportive measures and treat symptomatically.

For management of a suspected drug overdose, contact your regional poison control centre.

)

Find TALZENNA medical information:

Find TALZENNA medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

TALZENNA Quick Finder

Product Monograph
Download Product Monograph

Health Professional Information

5 Overdosage

There is no specific treatment in the event of TALZENNA overdose, and symptoms of overdose are not established. In the event of overdose, treatment with TALZENNA should be stopped, and physicians should consider gastric decontamination, follow general supportive measures and treat symptomatically.

For management of a suspected drug overdose, contact your regional poison control centre.

Resources

Didn’t find what you were looking for? 

Contact us

Call 1-800-463-6001*

*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: 1 866 723-7111.

To report an adverse event related to COMIRNATY, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

Canada Vigilance Program 

You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at 1-866-234-2345 or www.healthcanada.gc.ca/medeffect.